Investor Relations Activity Schedule from February 2 to March 4, 2024
An indicative announcement by Health Yuan Pharmaceutical Group Co., Ltd. on the stock option incentive plan to limit the exercise period
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on obtaining a clinical approval notice
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on approval for clinical trials of simeglutide injection
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the progress of providing guarantees
Announcement of Resolutions of the 29th Meeting of the 8th Board of Supervisors of Health Yuan Pharmaceutical Group Co., Ltd.
Opinions of the Supervisory Board of Health Yuan Pharmaceutical Group Co., Ltd. on the signing of a long-term loan agreement between the Company and International Finance Corporation
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. regarding the signing of a loan agreement between the Company and the international financial company International Finance Corporation
Announcement of Resolutions of the 37th Meeting of the Eighth Board of Directors of Health Yuan Pharmaceutical Group Co., Ltd.
Letter of independent opinion from the independent director of Health Yuan Pharmaceutical Group Co., Ltd. on matters to be considered at the 37th meeting of the 8th board of directors of the company
Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders of Health Yuan Pharmaceutical Group Co., Ltd.
Legal Opinion of Beijing Deheng (Shenzhen) Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Health Yuan Pharmaceutical Group Co., Ltd.
Record table of investor relations activities for December 2023 and January 2024
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on obtaining a clinical trial approval notice
Prompt announcement of Health Yuan Pharmaceutical Group Co., Ltd. on convening the 2024 First Extraordinary General Meeting of Shareholders
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on preparation for depreciation of calculated assets
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on independent directors voluntarily waiving receiving independent directors\' allowances
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on obtaining Philippine drug registration approval for compound ipratropium bromide solution for inhalation
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the progress of providing guarantees
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the independent exercise results and share changes of the company\'s 2022 stock options incentive plan for the fourth quarter of 2023
No Data